Database : MEDLINE
Search on : medicine [Words]
References found : 1865187 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 186519 go to page                         

  1 / 1865187 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 25699232
[Au] Autor:Chiu KW; Lu LS; Chiou SS
[Ad] Address:King-Wah Chiu, Lung-Sheng Lu, Shue-Shian Chiou, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.
[Ti] Title:High-level disinfection of gastrointestinal endoscope reprocessing.
[So] Source:World J Exp Med;5(1):33-9, 2015 Feb 20.
[Is] ISSN:2220-315X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:High level disinfection (HLD) of the gastrointestinal (GI) endoscope is not simply a slogan, but rather is a form of experimental monitoring-based medicine. By definition, GI endoscopy is a semicritical medical device. Hence, such medical devices require major quality assurance for disinfection. And because many of these items are temperature sensitive, low-temperature chemical methods, such as liquid chemical germicide, must be used rather than steam sterilization. In summarizing guidelines for infection prevention and control for GI endoscopy, there are three important steps that must be highlighted: manual washing, HLD with automated endoscope reprocessor, and drying. Strict adherence to current guidelines is required because compared to any other medical device, the GI endoscope is associated with more outbreaks linked to inadequate cleaning or disinfecting during HLD. Both experimental evaluation on the surveillance bacterial cultures and in-use clinical results have shown that, the monitoring of the stringent processes to prevent and control infection is an essential component of the broader strategy to ensure the delivery of safe endoscopy services, because endoscope reprocessing is a multistep procedure involving numerous factors that can interfere with its efficacy. Based on our years of experience in the surveillance of culture monitoring of endoscopic reprocessing, we aim in this study to carefully describe what details require attention in the GI endoscopy disinfection and to share our experience so that patients can be provided with high quality and safe medical practices. Quality management encompasses all aspects of pre- and post-procedural care including the efficiency of the endoscopy unit and reprocessing area, as well as the endoscopic procedure itself.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1502
[Da] Date of entry for processing:150220
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5493/wjem.v5.i1.33

  2 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25699231
[Au] Autor:Lubrano V; Balzan S
[Ad] Address:Valter Lubrano, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy.
[Ti] Title:Consolidated and emerging inflammatory markers in coronary artery disease.
[So] Source:World J Exp Med;5(1):21-32, 2015 Feb 20.
[Is] ISSN:2220-315X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Coronary artery disease is an event of atherosclerosis characterized by a chronic vascular inflammation. Risk factors like obesity, diabetes mellitus, hypertension, smoking, hypercholesterolemia and positive family history sometimes are not sufficiently adequate to the enhancement of cardiovascular risk assessment. In the past years numerous biomarkers, like C reactive protein, cytokines and adhesion molecules, have been observed to be related to adverse cardiovascular prognosis. Recently, several studies found an association among inflammatory biomarkers and cardiovascular diseases suggesting their utility to identify the risk of an acute ischemic event and the detection of vulnerable plaques. The emerging inflammatory markers are well divided for diagnosis and prognosis and plaque instability of coronary artery disease. Some of them, the lectin-like oxidized low density lipoprotein receptor-1 can be important both in diagnosis and in the evaluation of plaque instability, other are inserted in the above reported classification. The emerging inflammatory markers in acute-phase include amyloid A, fibrinogen and pentraxin 3 while myeloperoxidase, myeloid-related protein 8/14 and pregnancy-associated plasma protein-A are recognize markers of plaque instability. Lastly, some studies demonstrated that circulating miRNAs are involved in coronary artery disease, acute myocardial infarction and heart failure.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1502
[Da] Date of entry for processing:150220
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5493/wjem.v5.i1.21

  3 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25699230
[Au] Autor:Renaud-Gabardos E; Hantelys F; Morfoisse F; Chaufour X; Garmy-Susini B; Prats AC
[Ad] Address:Edith Renaud-Gabardos, Fransky Hantelys, Anne-Catherine Prats, Université de Toulouse, UPS, TRADGENE, EA4554, BP 84225, F-31432 Toulouse, France....
[Ti] Title:Internal ribosome entry site-based vectors for combined gene therapy.
[So] Source:World J Exp Med;5(1):11-20, 2015 Feb 20.
[Is] ISSN:2220-315X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Gene therapy appears as a promising strategy to treat incurable diseases. In particular, combined gene therapy has shown improved therapeutic efficiency. Internal ribosome entry sites (IRESs), RNA elements naturally present in the 5' untranslated regions of a few mRNAs, constitute a powerful tool to co-express several genes of interest. IRESs are translational enhancers allowing the translational machinery to start protein synthesis by internal initiation. This feature allowed the design of multi-cistronic vectors expressing several genes from a single mRNA. IRESs exhibit tissue specificity, and drive translation in stress conditions when the global cell translation is blocked, which renders them useful for gene transfer in hypoxic conditions occurring in ischemic diseases and cancer. IRES-based viral and non viral vectors have been used successfully in preclinical and clinical assays of combined gene therapy and resulted in therapeutic benefits for various pathologies including cancers, cardiovascular diseases and degenerative diseases.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1502
[Da] Date of entry for processing:150220
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5493/wjem.v5.i1.11

  4 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25699229
[Au] Autor:Söderberg-Nauclér C; Johnsen JI
[Ad] Address:Cecilia Söderberg-Nauclér, Experimental Cardiovascular Research Unit, Department of Medicine, Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
[Ti] Title:Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options.
[So] Source:World J Exp Med;5(1):1-10, 2015 Feb 20.
[Is] ISSN:2220-315X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:During the last years increasing evidence implies that human cytomegalovirus (CMV) can be attributed to human malignancies arising from numerous tissues. In this perspective, we will review and discuss the potential mechanisms through which CMV infection may contribute to brain tumors by affecting tumor cell initiation, progression and metastasis formation. Recent evidence also suggests that anti-CMV treatment results in impaired tumor growth of CMV positive xenografts in animal models and potentially increased survival in CMV positive glioblastoma patients. Based on these observations and the high tumor promoting capacity of this virus, the classical and novel antiviral therapies against CMV should be revisited as they may represent a great promise for halting tumor progression and lower cancer deaths.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1502
[Da] Date of entry for processing:150220
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5493/wjem.v5.i1.1

  5 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25698826
[Au] Autor:Litster A
[Ti] Title:Finding a home in shelter medicine.
[So] Source:Vet Rec;176(8):i-ii, 2015 Feb 21.
[Is] ISSN:2042-7670
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Inspired by a life-changing sabbatical in the USA, Annette Litster found her way into shelter medicine. An openness to change has fuelled a career full of twists and turns.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1136/vr.h891

  6 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25698821
[Au] Autor:Boyd CT; Jones BV
[Ad] Address:328 J. Otto Lottes Health Sciences Library, University of Missouri, Columbia, MO 65212, USA, e-mail: boydt@missouri.edu.
[Ti] Title:Postcards from the front.
[So] Source:Vet Rec;176(8):192-4, 2015 Feb 21.
[Is] ISSN:2042-7670
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Postcards provide an original insight into many aspects of human activity, including veterinary medicine. C. Trenton Boyd has collected a unique archive of some 8000 postcards from all over the world, dealing with almost every veterinary situation. Of these, over 1000 deal with the First World War, with about 600 directly related to the British Army and animal charities. Bruce Vivash Jones provides an outline of the war illustrated by a selection of images from the C. Trenton Boyd Postcard Collection.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1136/vr.h729

  7 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25256849
[Au] Autor:Fu X; Chen Y; Xie FN; Dong P; Liu WB; Cao Y; Zhang WJ; Xiao R
[Ad] Address:1 Research Center of Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing, P.R. China .
[Ti] Title:Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow.
[So] Source:Tissue Eng Part A;21(3-4):616-26, 2015 Feb.
[Is] ISSN:1937-335X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Mesenchymal stem cell (MSC) has great potential for both regenerative medicine and immunotherapy due to its multipotency and immunomodulatory property. The derivation of MSCs from human tissues involves an invasive procedure and the obtained MSCs often suffer from inconsistent quality. To overcome these issues, the approaches of deriving a highly potent and replenishable population of MSCs from human embryonic stem cells (hESCs) were established. However, few studies compared the immunological characteristics of MSCs derived from hESCs with tissue-derived MSCs or demonstrated differences and the underlying mechanisms. Here, we differentiated H9 hESCs into MSC-like cells (H9-MSCs) through an embryoid body outgrowth method and compared the immunological characteristics of H9-MSCs with bone marrow-derived MSCs (BMSCs). Both sources of derived cells exhibited typical MSC morphologies and surface marker expressions, as well as multipotency to differentiate into osteogenic and adipogenic lineages. A immunological characterization study showed that H9-MSCs and BMSCs had similar immunoprivileged properties without triggering allogeneic lymphocyte proliferation as well as equivalent immunosuppressive effects on T-cell proliferation induced by either cellular or mitogenic stimuli. Flow cytometry analysis revealed a lower expression of human major histocompatability complex class II molecule human lymphocyte antigen (HLA)-DR and a higher expression of coinhibitory molecule B7-H1 in H9-MSCs than in BMSCs. Interferon gamma (IFN-γ) is a proinflammatory cytokine that can induce the expression of HLA class II molecules in many cell types. Our results showed that pretreatment of H9-MSCs and BMSCs with IFN-γ did not change their immunogenicity and immunosuppressive abilities, but increased the difference between H9-MSCs and BMSCs for their expression of HLA-DR. Further detection of expression of molecules involved in IFN-γ signaling pathways suggested that the lower expression of HLA-DR in H9-MSCs could be partially attributed to the lower expression and the less nuclear translocation of its transcriptional factor CIITA. The present study provides evidence that the hESC-derived MSCs share similar immunogenicity and immunosuppressive abilities with BMSCs, but differ in the expression profile of immunological markers and the responsiveness to certain inflammatory cytokines, which suggests that H9-MSCs could be a safe and efficient candidate for MSC treatment in patients with inflammatory disorders.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1089/ten.TEA.2013.0651

  8 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25234861
[Au] Autor:Ishkitiev N; Yaegaki K; Imai T; Tanaka T; Fushimi N; Mitev V; Okada M; Tominaga N; Ono S; Ishikawa H
[Ad] Address:1 Department of Oral Health, School of Life Dentistry at Tokyo, Nippon Dental University , Tokyo, Japan .
[Ti] Title:Novel management of acute or secondary biliary liver conditions using hepatically differentiated human dental pulp cells.
[So] Source:Tissue Eng Part A;21(3-4):586-93, 2015 Feb.
[Is] ISSN:1937-335X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The current definitive treatment for acute or chronic liver condition, that is, cirrhosis, is liver transplantation from a limited number of donors, which might cause complications after donation. Hence, bone marrow stem cell transplantation has been developed, but the risk of carcinogenesis remains. We have recently developed a protocol for hepatic differentiation of CD117(+) stem cells from human exfoliated deciduous teeth (SHED). In the present study, we examine whether SHED hepatically differentiated (hd) in vitro could be used to treat acute liver injury (ALI) and secondary biliary cirrhosis. The CD117(+) cell fraction was magnetically separated from SHED and then differentiated into hepatocyte-like cells in vitro. The cells were transplanted into rats with either ALI or induced secondary biliary cirrhosis. Engraftment of human liver cells was determined immunohistochemically and by in situ hybridization. Recovery of liver function was examined by means of histochemical and serological tests. Livers of transplanted animals were strongly positive for human immunohistochemical factors, and in situ hybridization confirmed engraftment of human hepatocytes. The tests for recovery of liver function confirmed the presence of human hepatic markers in the animals' blood serum and lack of fibrosis and functional integration of transplanted human cells into livers. No evidence of malignancy was found. We show that in vitro hdSHED engraft morphologically and functionally into the livers of rats having acute injury or secondary biliary cirrhosis. SHED are readily accessible adult stem cells, capable of proliferating in large numbers before differentiating in vitro. This makes SHED an appropriate and safe stem cell source for regenerative medicine.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1089/ten.TEA.2014.0162

  9 / 1865187 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25159486
[Au] Autor:Liu Y; Yang R; Shi S
[Ad] Address:1 Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory for Tooth Regeneration and Function Reconstruction, Capital Medical University School of Stomatology , Beijing, China .
[Ti] Title:Systemic Infusion of Mesenchymal Stem Cells Improves Cell-Based Bone Regeneration via Upregulation of Regulatory T Cells.
[So] Source:Tissue Eng Part A;21(3-4):498-509, 2015 Feb.
[Is] ISSN:1937-335X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Mesenchymal-stem-cell-based regenerative medicine is a promising approach for functional tissue reconstruction. A recent study showed that host immune cells regulated bone marrow mesenchymal stem cell (BMMSC)-mediated tissue regeneration. However, it is unknown whether systemic infusion of BMMSCs, which induces immune tolerance, affects cell-based tissue regeneration. In this study, we showed that BMMSCs possessed an immunomodulatory function in vitro. Moreover, systemic infusion of BMMSCs reduced IFN-γ and TNF-α levels in the implantation sites via upregulation of regulatory T cells (Tregs), resulting in marked enhancement of cell-based bone regeneration, but with only limited contribution by BMMSC homing. Further, we showed that systemic BMMSC infusion significantly improved cell-based repair of critical-sized calvarial defects in a murine model. These results suggested a new approach to enhance cell-based bone regeneration.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1089/ten.TEA.2013.0673

  10 / 1865187 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25695147
[Au] Autor:Schuetz P; Aujesky D; Müller C; Müller B
[Ad] Address:Medical University Clinic of the Medical Faculty University of Basel, Kantonsspital Aarau, Switzerland....
[Ti] Title:Biomarker-guided personalised emergency medicine for all - hope for another hype?
[So] Source:Swiss Med Wkly;145:w14079, 2015.
[Is] ISSN:1424-3997
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Polymorbid patients, diverse diagnostic and therapeutic options, more complex hospital structures, financial incentives, benchmarking, as well as perceptional and societal changes put pressure on medical doctors, specifically if medical errors surface. This is particularly true for the emergency department setting, where patients face delayed or erroneous initial diagnostic or therapeutic measures and costly hospital stays due to sub-optimal triage. A "biomarker" is any laboratory tool with the potential better to detect and characterise diseases, to simplify complex clinical algorithms and to improve clinical problem solving in routine care. They must be embedded in clinical algorithms to complement and not replace basic medical skills. Unselected ordering of laboratory tests and shortcomings in test performance and interpretation contribute to diagnostic errors. Test results may be ambiguous with false positive or false negative results and generate unnecessary harm and costs. Laboratory tests should only be ordered, if results have clinical consequences. In studies, we must move beyond the observational reporting and meta-analysing of diagnostic accuracies for biomarkers. Instead, specific cut-off ranges should be proposed and intervention studies conducted to prove outcome relevant impacts on patient care. The focus of this review is to exemplify the appropriate use of selected laboratory tests in the emergency setting for which randomised-controlled intervention studies have proven clinical benefit. Herein, we focus on initial patient triage and allocation of treatment opportunities in patients with cardiorespiratory diseases in the emergency department. The following five biomarkers will be discussed: proadrenomedullin for prognostic triage assessment and site-of-care decisions, cardiac troponin for acute myocardial infarction, natriuretic peptides for acute heart failure, D-dimers for venous thromboembolism, C-reactive protein as a marker of inflammation, and procalcitonin for antibiotic stewardship in infections of the respiratory tract and sepsis. For these markers we provide an overview on physiopathology, historical evolution of evidence, strengths and limitations for a rational implementation into clinical algorithms. We critically discuss results from key intervention trials that led to their use in clinical routine and potential future indications. The rational for the use of all these biomarkers, first, tackle diagnostic ambiguity and consecutive defensive medicine, second, delayed and sub-optimal therapeutic decisions, and third, prognostic uncertainty with misguided triage and site-of-care decisions all contributing to the waste of our limited health care resources. A multifaceted approach for a more targeted management of medical patients from emergency admission to discharge including biomarkers, will translate into better resource use, shorter length of hospital stay, reduced overall costs, improved patients satisfaction and outcomes in terms of mortality and re-hospitalisation. Hopefully, the concepts outlined in this review will help the reader to improve their diagnostic skills and become more parsimonious laboratory test requesters.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Js] Journal subset:IM
[St] Status:In-Data-Review


page 1 of 186519 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information